Amgen v. Sandoz: Next Biosimilar Bout Begins Over State Law Claims
Executive Summary
In the ongoing Zarxio dispute, US appeals court takes up question left open by Supreme Court as to whether innovator company can seek remedy under state law if a biosimilar sponsor does not engage in the "patent dance" by providing its application and manufacturing information.